RadioPharmaceuticals
ID: W81K0025QA122Type: Solicitation
AwardedAug 5, 2025
$427K$427,002
AwardeeRLS (USA) INC. Lake Mary FL 32746 USA
Award #:W81K0025PA143
Overview

Buyer

DEPT OF DEFENSEDEPT OF THE ARMYW40M MRC0 WESTJBSA FT SAM HOUSTON, TX, 78234-4504, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Department of Defense, specifically the Department of the Army, is soliciting proposals for the provision of radiopharmaceuticals to the Nuclear Medicine Service at Carl R. Darnall Army Medical Center in Fort Hood, Texas. The contract encompasses an initial performance period from October 1, 2025, to September 30, 2026, with three optional extension periods, and requires the contractor to ensure compliance with U.S. Pharmacopeia guidelines for the delivery of specified radioactive pharmaceuticals, including Gallium Citrate and Tc-99m compounds. This procurement is critical for supporting medical services within the military healthcare system, emphasizing the importance of security, privacy, and regulatory compliance in handling sensitive medical products. Interested vendors, particularly women-owned small businesses, should review the solicitation documents and submit their proposals by the specified deadlines, with inquiries directed to primary contact Shenecqua Soares at shenecqua.n.soares.civ@health.mil or secondary contact Timothy T. Hoerz at timothy.t.hoerz.civ@mail.mil.

    Point(s) of Contact
    Files
    Title
    Posted
    This document outlines the amendment process for federal solicitations or contracts, specifying that offers must acknowledge receipt of the amendment by a deadline to avoid rejection. It details three permissible methods for acknowledgment: returning the signed amendment, noting receipt on the offer copies, or through a separate communication that references the solicitation and amendment numbers. The document also allows for changes to be made to existing offers via similar communication methods before the opening date. Additionally, it addresses contract modifications, indicating that changes can be made through various authorities and outlining requirements for contractor signatures. Overall, this document serves to guide potential bidders on complying with solicitation amendments and maintaining effective communication with the contracting authority in the context of federal solicitations and contracts.
    The government contract outlines the provision and delivery of radiopharmaceuticals to the Nuclear Medicine Service at Carl R. Darnall Army Medical Center in Fort Cavazos, TX, with an initial performance period from October 1, 2025, to September 30, 2026, plus three optional years. The contractor is responsible for installation, scientific studies, and maintenance, with specific delivery times for routine and STAT orders. The doses must comply with U.S. Pharmacopeia guidelines. Security protocols require contractor personnel to adhere to military regulations, including background checks and training on identifying suspicious activities. The contractor must comply with health privacy laws, ensuring protection for Personally Identifiable Information (PII) and Protected Health Information (PHI) according to Federal and DoD regulations. Invoicing requires itemized submissions within 30 days post-service, and all contractor employees must follow tobacco-free policies on the medical campus. The contractor is prohibited from hiring individuals listed on exclusion lists, necessitating ongoing checks against these lists. The document emphasizes the importance of maintaining security, privacy, and regulatory compliance while providing medical services.
    The document outlines a solicitation for commercial products and services specifically aimed at women-owned small businesses (WOSB) within the federal contracting framework. It details the requirements for various radioactive pharmaceuticals, including items such as Gallium Citrate and Tc-99m compounds. The solicitation specifies delivery terms, payment codes, and the conditions under which acceptance and inspection will occur, largely directed towards government locations like Fort Cavazos. The key points include the contractor's obligations to provide specified quantities of the radioactive products, with fixed pricing arrangements, adhering to the guidelines of the Federal Acquisition Regulation (FAR). It emphasizes the importance of proper handling and compliance for sensitive medical products. The presence of both option and line items illustrates the scope of the offerings, alongside specific instructions for both proposal submission and the eventual acceptance of delivered products. Overall, the document serves to facilitate procurement from women-owned businesses, promoting inclusivity in government contracts while addressing critical medical supply needs.
    Lifecycle
    Title
    Type
    RadioPharmaceuticals
    Currently viewing
    Award
    Presolicitation
    Similar Opportunities
    Radiopharmaceutical Laboratory Services (RLS) MAMC
    Dept Of Defense
    The Department of Defense, specifically the Madigan Army Medical Center, is conducting market research to identify qualified vendors capable of providing comprehensive Radiopharmaceutical Laboratory Services (RLS). The procurement aims to ensure that vendors can meet stringent requirements, including compliance with FDA standards, The Joint Commission accreditation, and the ability to deliver a range of specified radiopharmaceuticals on a 24/7 basis, including urgent requests. These services are critical for supporting medical operations that rely on radiopharmaceuticals for diagnostics and treatment. Interested parties must submit their capability statements to Cindy Means and Scott Barr by December 19, 2025, at 4:00 PM Pacific Time, detailing their qualifications and ability to meet the outlined requirements.
    6505--Notice of Intent to Award a Sole Source Procurement - Xofigo Radium-223 dichloride
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Network Contracting Office 17, intends to award a sole source, firm-fixed-price contract to Cardinal Health for the procurement of 660 units of XOFIGO® (Radium-223 dichloride). This procurement is based on a letter from Bayer Healthcare, which designates Cardinal Health as the sole distributor of XOFIGO® in the United States, highlighting the critical nature of this pharmaceutical in treating specific medical conditions. Interested parties may submit capability statements or proposals within seven days of the notice's publication, with the deadline set for December 19, 2025; otherwise, the contract will be awarded to Cardinal Health without further notice. For inquiries, contact Vance Farrell at vance.farrell@va.gov or call 210-694-6379.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Military Treatment Facilities (MTFs) and TRICARE pharmacies. This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs, which will be evaluated by the Pharmacy and Therapeutics (P&T) Committee. Key drugs under consideration include newly approved agents for lung cancer, antihypertensive agents, oncological agents, diuretics, antilipidemics, and targeted immunomodulatory biologics, with quotes due by January 5, 2026, for a committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Tracy Banks or Julia Trang via email for further details and ensure compliance with submission requirements outlined in the RFQ document HT9402-26-Q-9103.
    Radiology Blanket Purchase Agreement
    Dept Of Defense
    The Department of Defense, specifically the Department of the Army, is seeking proposals for a Radiology Blanket Purchase Agreement (BPA) to provide diagnostic imaging services at Fort Knox, Kentucky. This procurement is set aside for small businesses under NAICS code 621512, which encompasses Diagnostic Imaging Centers, and requires offerors to submit a completed BPA price list as part of their proposals. The services are critical for supporting military healthcare operations, ensuring timely and effective radiological assessments. Proposals are due by 2:00 PM Eastern Daylight Time (EDT) on December 18, 2025, and must be submitted via email to Justin Balster at justin.balster2.civ@health.mil and MAJ Jason Holck at jason.t.holck.mil@health.mil, with all offerors required to be registered in the System for Award Management (SAM) prior to award.
    6505--Pylarify 2026 (VA-26-00025867) RFI
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking qualified sources to provide F18 PSMA Pylarify, a radiopharmaceutical used for positron emission tomography (PET) imaging of prostate cancer, to the Baltimore VA Medical Center. The procurement aims to identify contractors capable of manufacturing, preparing, and transporting this specialized radiopharmaceutical in compliance with stringent regulatory standards, including USNRC, DOT, and FDA guidelines. Pylarify is critical for diagnosing prostate cancer by identifying PSMA-positive lesions, thus playing a vital role in patient care. Interested parties must submit their responses, including company information and qualifications, by December 17, 2025, at 10:00 AM EST, to Contract Specialist Michael Jones at michael.jones16@va.gov.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Medical Physics Testing
    Dept Of Defense
    The Department of Defense, through the Department of the Army, is seeking proposals for Medical Physics Testing services under a combined synopsis/solicitation format. This procurement is specifically set aside for small businesses, with a focus on commercial items categorized under NAICS code 541990, which encompasses all other professional, scientific, and technical services. The selected contractor will play a crucial role in ensuring the quality and safety of medical, dental, and veterinary equipment and supplies, which is vital for maintaining health standards within military facilities. Proposals are due by 2:00 PM Eastern Daylight Time on December 18, 2025, and must be submitted via email to the designated contacts, Justin Balster and Jason Holck, who will confirm receipt of all submissions.
    6505--Supply, RADIOPHARMACEUTICALS DATSCAN - NBD 1/1 Indianapolis VAMC
    Veterans Affairs, Department Of
    The Department of Veterans Affairs, specifically the Indianapolis Veterans Affairs Medical Center (VAMC), intends to issue a sole source contract to Medi-Physics, Inc. for the procurement of 20 units of DaTscan Ioflupane, a radiopharmaceutical essential for conducting diagnostic tests. This acquisition is based on the authority of FAR Part 6.302-1, which allows for negotiation with only one responsible source, as Medi-Physics, Inc. is the sole vendor on the Federal Supply Schedule (FSS) contract for this product. The contract is anticipated to be a firm-fixed price agreement with no option years, and responses to this notice must be submitted by 12:00 pm on December 17, 2025, to the primary contact, Rachel MacRae, at rachel.macrae@va.gov or by phone at 734-222-4326.